妊娠期肝炎病毒多重感染对母婴的影响

目的 探讨妊娠期肝炎病毒多重感染对母婴的影响。方法 对1994年1月至1999年12月在我院产前检查,肝功能异常的孕妇行甲、乙、丙、丁、戊等5种肝炎病毒标记物检测,其中确诊为肝炎病毒多重感染者32例（多重感染组）,确诊为肝炎病毒单一感染者32例（单一感染组）,对两组母儿并发症及预后进行观察比较。结果 两组丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、血清总胆红素（TBIL）水平比较,差异无显著性（P＞0．05）。多重感染组乙型肝炎病毒e抗原（HBeAg)阳性率（35．7％）显著低于单一感染组（76．9％,P＜0．05）,而乙型肝炎病毒e抗体（HBeAb)阳性率（57．1％）显著高于单一感染组（15．4％,P＜0．01）。多重感染组孕妇妊娠高血压综合征（妊高征）、产后出血、重症肝炎、死亡的发生率与单一感染组比较,差异无显著性（P＞0．05）。而多重感染组胎膜早破、早产的发生率（28．1％,25．0％）明显高于单一感染组（6．3％、3．1％,P＜0．05）;胎儿宫内窘迫及新生儿窒息的发生率（31．3％,25．0％）显著高于单一感染组（9．4％、0．0％,P＜0．05、P＜0．01）。结论 妊娠期肝炎病毒多重感染对孕妇的影响无明显加重,而对围产儿的影响较为明显;应加强孕期保健,防止胎膜早破及早产的发生。     

妊娠合并细菌性阴道病的研究

目的：确定妊娠合并细菌性阴道病（ＢＶ）的发病情况，探讨妊娠合并ＢＶ与不良妊娠结局的关系。方法：根据临床表现和阴道革兰染色涂片镜检，对不同孕期的３８０名健康孕妇进行ＢＶ发病情况调查，并对其妊娠结局进行随诊。结果：妊娠合并ＢＶ的检出率为６．８％（２６／３８０）。妊娠合并ＢＶ孕妇的产褥感染、新生儿感染及新生儿黄疸的发生率，依次为１４．３％（３／２１）、９．５％（２／２１）及２３．８％（５／２１），高于无合并ＢＶ者（分别为２．２％、１．３％及５．４％，Ｐ＜０．０５，Ｐ＜０．０５，Ｐ＜０．００５）。结论：妊娠合并ＢＶ与母儿感染有关，有必要对妊娠合并ＢＶ孕妇进行治疗。     

Overview of infection causing hepatitis other than non-A to E hepatitis virus during pregnancy

Abnormal liver function tests during pregnancy are common. While hepatic injury during pregnancy mostly has minimal adverse influence on maternal and fetal outcomes, severe maternal and fetal morbidities, and even death, sometimes occur. Here, we review the epidemiology, clinical features, diagnosis, and management of hepatitis during pregnancy caused by the less common pathogens, including Epstein–Barr virus (EBV), cytomegalovirus (CMV), herpes simplex viruses (HSVs), dengue fever, malaria, leptospirosis, Q fever, typhoid fever, and other occasional infections, as well as the implications on breastfeeding of the infants. Hepatitis during pregnancy with fever and systemic clinical presentations, which are not attributable to the common infectious agents, should raise the suspicion of infection with above-mentioned pathogens, and appropriate laboratory tests are required. Early recognition of severe hepatitis or acute liver failure is critical in initiating appropriate and specific therapy, together with systemic supportive care, to reduce maternal and fetal mortality and long-term sequelae.     

Hepatitis B – Vertical transmission and the prevention of mother-to-child transmission

Hepatitis B virus (HBV) infection is the commonest cause of chronic hepatitis, with an estimated global prevalence of 3.5%, and which leads to significant morbidity and mortality. Mother-to-child transmission (MTCT) during pregnancy is the leading form of transmission in endemic populations, and its interruption is thus crucial as the initial step in the elimination of HBV infection, notwithstanding the availability of potent antiviral medications. The risk of MTCT is dramatically reduced by timely neonatal HBV vaccination and the administration of hepatitis B immunoglobulin after birth in high-risk infants. Maternal HBV DNA quantification during pregnancy allows the assessment of the risk of newborn immunoprophylaxis failure (IF). Maternal antiviral treatment in highly viremic women can reduce the risk of IF. However, the optimal HBV DNA cutoff level for the initiation of antiviral treatment remains to be determined.     

Hepatitis B – chronic carrier status and pregnancy outcomes: An obstetric perspective

Antenatal screening for hepatitis B surface antigen (HBsAg) only identifies women with hepatitis B virus (HBV) infection for neonatal immunoprophylaxis. It does not reflect the phase of chronic infection, viral genotype and activity, hepatic inflammation, or other co-existing liver disorders. Coinfection with other viruses and micro-organisms may also be present. These factors in various combinations can impact pregnancy outcomes, and they are probably responsible for the conflicting literature on this issue. Pregnancy complications may interact with maternal HBV infection and hepatitis flares, leading to serious and lethal complications. Hepatitis flares are common especially postpartum, and they are unpredictable and unpreventable with antiviral treatment. Evidence on the association between HBsAg seropositivity with gestational diabetes mellitus, preterm birth, increased foetal growth, and reduced pregnancy hypertensive disorders is stronger than other adverse pregnancy outcomes. Baseline assessment of liver function, and viral markers and activity, can delineate the truly high-risk pregnancies for close monitoring.     

Viral infections in pregnancy

Viral infections are a common complication of pregnancy and in some cases, can have profound effects for the unborn fetus. The human herpesvirus family is composed of large, enveloped DNA viruses that have close structural similarity. The family includes the herpes simplex viruses types 1 and 2, varicella zoster virus, Epstein Barr virus, cytomegalovirus (CMV), and human herpes viruses types 6, 7 and 8. These viruses all share the ability to establish latency and reactivate at a later time. Structural fetal abnormalities can result from intrauterine infection and transmission of the infection during the pregnancy or at the time of delivery can result in important neonatal disease. Human parvovirus B19 is a DNA virus with strong tropism for erythroid precursors and infection during pregnancy can result in fetal hydrops and stillbirth. The causative agents of hepatitis are hepatotropic viruses termed hepatitis A, B, C, D (deltavirus) and E. All except hepatitis B virus are RNA viruses. Vertical transmission of maternal infection with hepatitis B and C can result in significant long term sequelae.     

Viral hepatitis during pregnancy

Viral hepatitis is one of the most common liver diseases appearing during pregnancy. Prevention against hepatotropic viruses is restricted due to lack of vaccines being effective in induction of efficient immunization in the majority of these microorganisms. In general, there is no possibility of active immunization against hepatotropic viruses except type A and B viral hepatitis. An issue of viral hepatitis in pregnancy as an aspect of potential risk factor connected with infection of pregnant women and a fetus has been described in this paper. Furthermore, the most important topics in the field of the epidemiology, prophylaxis and possible treatment options of viral hepatitis A, B, C, D, E and G have been discussed. The newest reports of pregnant women lamivudine therapy as a preventive treatment against vertical transmission during delivery have been reviewed. Rarly diagnosed viral hepatitis caused by herpes simplex virus, cytomegalovirus, Epstein-Barr virus and adenoviruses have been characterized as well.     

Influenza and tetanus, diphtheria, and acellular pertussis vaccinations during pregnancy

Vaccinations in pregnancy are an important aspect of prenatal care and of improving not only maternal health but also neonatal outcomes. Only 2 vaccines are specifically recommended during pregnancy: influenza and tetanus, diphtheria, and acellular pertussis (Tdap). Because influenza illness disproportionately affects pregnant women compared with other populations, annual prevention of influenza illness is recommended for all women who will be pregnant during influenza season (October to May). Influenza vaccination has been recently reported to also result in decreased febrile respiratory illnesses in the newborn, likely through passive antibody transfer. Pertussis infection rates are rising in the United States as vaccine-induced immunity wanes, with the mortality burden primarily seen in infants aged <6 months. Pertussis immunization with Tdap is now recommended for all pregnant women during the late second (>20 weeks) or third trimester with the intent to both protect the pregnant woman and provide passive antibody to the infant before vaccination at 2 months of age. Provider support for these recommendations regarding both annual influenza vaccination and postpartum Tdap vaccination during pregnancy is critical to ensuring vaccine delivery and improving both maternal and fetal health. The article reviews the epidemiology and clinical aspects of influenza and pertussis infection with particular attention to pregnancy and recommendations for vaccination in these women. TARGET AUDIENCE: Obstetricians and gynecologists, ophthalmologists, neurologists, family physicians, emergency room physicians LEARNING OBJECTIVES: After completing this CME activity, obstetricians and gynecologists should be better able to analyze how influenza infection disproportionally affects pregnant women. Assess how influenza vaccination improves maternal and likely neonatal outcomes. Evaluate pertussis infection and immunity in adults, and counsel pregnant women as to the benefits of Tdap vaccination, particularly for the infant.     

孕妇产前进行免疫阻断与新生儿乙型肝炎基因疫苗免疫效果关系的研究

目的探讨采用乙型肝炎免疫球蛋白(HBIG)阻断孕妇乙型肝炎病毒(HBV)感染对新生儿乙型肝炎(简称乙肝)基因疫苗免疫效果的影响。方法对55例HBV标志物阳性孕妇于产前28周、32周和36周分别给予HBIG 200IU免疫阻断作为阻断组；31例HBV标志物阳性孕妇未给予HBIG免疫阻断作为未阻断组；同期选择HBV标志物阴性孕妇42例作为对照组。对三组新生儿分别给予乙肝基因疫苗的免疫接种，并分别于1个月、2个月、7个月和12个月龄采集外周血检测HBV标志物及丙氨酸转氨酶(ALT)。结果阻断组、未阻断组和对照组新生儿免疫保护率分别为87.3%(48/55)、77.4%(24/31)和97.6%(41/42)；未阻断组与对照组间比较具有统计学意义(P<0.01)；对“大三阳”孕妇的阻断效果最好，新生儿抗HBs阳转率从33.3%上升到71.4%。结论对HBV感染孕妇采用HBIG免疫阻断，可以降低宫内感染及母婴传播的发生率；分娩时孕妇HBV感染状态对新生儿抗HBs阳转率可能产生一定程度的影响。     

Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy

We compared maternal and neonatal outcomes in diabetic pregnancies treated with either insulin glargine or neutral protamine Hagedorn (NPH) insulin. We performed a retrospective chart review of diabetic pregnant patients using the Diabetes Care Center of Wake Forest University during the years 2000 to 2005. Outcomes of interest included maternal hemoglobin A1C, average fasting and 2-hour postprandial blood sugars, mode of delivery, birth weight, 5-minute Apgar score < 7, umbilical artery pH < 7.20, incidence of neonatal hypoglycemia, and pregnancy complications. A total of 52 diabetic pregnant patients were included in this study. Twenty-seven women used insulin glargine. A total of 13 women used insulin glargine during the first trimester. Glycemic control was similar in women who used NPH insulin and insulin glargine, as determined by hemoglobin A1C levels and mean blood sugar values. There were no differences in mode of delivery, average birth weight, or neonatal outcomes. Maternal and fetal/neonatal outcomes appear similar in pregnant diabetic women who use either NPH insulin or insulin glargine in combination with a short-acting insulin analogue to achieve adequate glycemic control during pregnancy. Insulin glargine appears to be an effective insulin analogue for use in women whose pregnancies are complicated by diabetes.     

妊娠合并甲状腺功能减退症或亚临床甲状腺功能减退症77例临床分析

目的 探讨甲状腺功能减退症(简称甲减)及亚临床甲减对孕产妇妊娠结局及围产儿的影响.方法 回顾性分析2005年1月至2008年3月在北京协和医院妊娠合并甲减(57例)或亚临床甲减(20例)分娩孕妇77例,随机选取同期分娩的正常孕妇79例作为对照,分析三组孕妇的一般临床资料、产时产后并发症及嗣产儿结局.结果 3年间我院妊娠合并甲减的患病率为0.74%,合并亚临床甲减的患病率为0.26%,凡呈逐年升高趋势.妊娠合并甲减组新生儿平均出生体重低于对照组[(3191.8±659.4)g和(3301.9±423.1)g,P<0.05],妊娠期糖代谢异常发生率(24.6%)及小于胎龄儿的发生率(12.3%)均高于对照组(分别为11.4 %和2.5%)(P<0.05).妊娠合并亚临床甲减组各项妊娠期并发症的发生率与对照组比较,均无统计学意义.结论 妊娠合并甲减及亚临床甲减的患病率逐年上升,即使经过治疗,甲减或亚临床甲减孕妇小于胎龄儿等并发症的发生几率仍增加.对高危人群早期筛查、充分治疗是改善妊娠结局的最好方法.     

Viral hepatitis: from A to E, and beyond?

Identification of hepatitis viruses A-E has enabled researchers to investigate the epidemiology, pathogenesis, sequelae, and possible means of prevention of these infections. This knowledge also provides a basis for further study of the pathological significance of candidate hepatitis viruses. With improvements in hygiene in many parts of the world, hepatitis A virus infection has decreased markedly. However, this success has the unintended consequence of rendering a large percentage of the younger population susceptible to hepatitis A virus infection. Fortunately, effective active immunization for hepatitis A virus is now available. Hepatitis B remains a common condition, especially in Asia and Africa which have high prevalences of chronic infection. Chronic hepatitis B carriers serve as reservoirs of infection for the community and are at risk of chronic liver disease and hepatocellular carcinoma. A mass immunization program in Taiwan has been remarkably successful in reducing the prevalence of chronic hepatitis B infection. Genotypes of the hepatitis B viruses may be associated with the severity of liver disease and the responses to therapies. Hepatitis C is another important cause of death worldwide. The infection easily becomes refractory and the chronicity contributes to the development of cirrhosis and hepatocellular carcinoma. Although no effective immunization is currently available for hepatitis C, it can be controlled by preventative measures and recently developed interferon-based treatments, especially in combination with ribavirin. The prevalence of hepatitis D has markedly decreased in the last decade and new cases are now rarely encountered. Hepatitis E is endemic in limited areas and travel to these areas appears to be the main risk factor for contracting the infection. Several new candidate hepatitis viruses have been identified, including GB virus-C, TT virus, and SEN virus, but none of these has been shown to cause hepatitis, and they may be passenger viruses.     

妊娠合并乙型肝炎病毒感染围分娩期管理

对乙型肝炎(乙肝)病毒感染孕妇采取合理的围分娩期管理以阻断母婴垂直传播是降低我国慢性乙肝感染率的关键。新生儿出生后及时注射乙肝免疫球蛋白,并按照0、1、6方案接种乙肝疫苗,可有效阻断乙肝的围分娩期传播。孕妇在晚孕期进行抗病毒治疗可能通过降低母体病毒水平而减少围分娩期传播风险,但抗病毒药物对胎儿的安全性仍需进一步验证。     

Update on the management of hepatitis B and C infections in the neonatal period

Hepatitis B virus and hepatitis C virus have received a significant amount of attention in recent years, and both viruses share a significant amount of similarities with one another beyond just that they both primarily target the liver. In recent years, cases of both infections have been fueled by a nationwide epidemic of injection drug use. Most relevant to this audience, they are both transmitted from mother to child. The increased cases in young adults combined with mother to child transmission translate into more exposed infants that will need to be managed and followed. Screening of pregnant women for hepatitis B infection coupled with appropriate treatment and prophylaxis measures are incredibly effective to preventing transmission. Prevention of hepatitis C infection is not yet possible, but advances in antiviral therapy make interruption of transmission a future possibility.     

孕晚期注射乙肝免疫球蛋白阻断乙肝病毒宫内感染的Meta分析

目的:综合评价孕晚期注射乙肝免疫球蛋白阻断乙肝病毒宫内感染的效果和安全性。方法:应用Revman 4.2.10软件,对计算机检索后筛选出的5项随机对照研究采用固定模型进行分析。结果:孕晚期注射HB IG组宫内感染发生率显著低于对照组[RR=0.40,95%CI(0.30,0.54)]。结论:孕晚期注射乙肝免疫球蛋白可有效地阻断乙肝病毒宫内感染。     

Perinatal echovirus and group B coxsackievirus infections

Enteroviral infections late in pregnancy are common, especially during periods of high prevalence of community infection. Most of these infections, however, are not associated with significant maternal or neonatal disease. Conversely, as many as 65 per cent of women who give birth to infants with proven enteroviral infection have symptomatic disease during the perinatal period. Maternal echovirus or coxsackievirus B infections are not associated with an increased risk of spontaneous abortions, but stillbirths late in pregnancy have been described. Although a slightly increased risk for congenital heart defects and urogenital anomalies has been reported for the offspring of women who seroconverted to the group B coxsackievirus during pregnancy, these data are highly tentative. Transmission of enteroviruses from mother to infant is relatively common (30-50 per cent) and may occur through contact with maternal secretions during vaginal delivery, blood, or upper respiratory tract secretions. Intrauterine transmission has been documented, but its frequency is unknown. Postnatal transmission from maternal or nonmaternal sources also occurs regularly. Neonatal disease may range from inapparent infection to overwhelming systemic illness and death. Common clinical syndromes associated with neonatal enteroviral infections are meningoencephalitis, pneumonia, myocarditis, and hepatitis. The severity and outcome of perinatally acquired enteroviral infection is influenced by several factors, including the virus strain involved, mode of transmission, and presence of passively acquired serotype-specific maternal antibody. Newborn nursery outbreaks of nonpolio enteroviral infections usually coincide with seasonal peaks of enteroviral disease in the community. These outbreaks have been due mostly to echovirus 11 or group B coxsackievirus serotypes 1 to 5 and are associated with attack rates of up to 50 per cent.     

The use of low-molecular-weight heparins in pregnancy--how safe are they?

PURPOSE OF REVIEW: Low-molecular-weight heparins are in widespread use during pregnancy. As with every treatment in pregnant patients, concerns have been raised about the safety of Low-molecular-weight heparins. The purpose of the present article is to review recent advances, published during the past year, that have studied the maternal, fetal, and neonatal safety of Low-molecular-weight heparins in pregnant women. RECENT FINDINGS: Low-molecular-weight heparins do not increase the risk of maternal bleeding during pregnancy. Closed management is needed during the peripartum period, and discontinuing Low-molecular-weight heparins at least 12 h before delivery seems sufficient to prevent post-partum haemorrhage. The incidence of Low-molecular-weight heparins-induced immune reaction is low. Fondaparinux or danaparoid may be used as an alternative option in pregnant women with heparin-induced thrombocytopenia. Long-term Low-molecular-weight heparins therapy may be associated with osteopenia. Calcium vitamin D supplementation during pregnancy may reduce the risk of Low-molecular-weight heparins-induced osteoporosis. As Low-molecular-weight heparins do not cross the placenta, no fetal or neonatal complication has been reported. Beyond the safety question, Low-molecular-weight heparins have the potential to improve the live-birth rate in high-risk pregnancies (antiphospholipid syndrome, thrombophilia, or recurrent fetal loss). SUMMARY: Recent studies have confirmed the safety of Low-molecular-weight heparins therapy during pregnancy. The risk of potential side effects is low for both the mother and the neonate.     

Hepatitis B and C virological tests: interpretation and practical results in women

Chronic Hepatitis C or B infection can lead to liver cirrhosis and hepatocellular carcinoma. In women, these viral infections can be responsible for transmission to the spouse and to the child during delivery. Concerning the hepatitis C virus, the factors most strongly associated with infection are injection-drug use and blood transfusion before 1991. The risk of mother-to-infant transmission of hepatitis C virus is uncommon (5 per cent): except for the viral eradication before pregnancy, there is no preventive measure to propose. Pregnancy is not contra-indicated. Hepatitis C virus transmission by sexual contact in steady monogamous partnerships is low (< 1 per cent). In most developed parts of the world where the prevalence of chronic hepatitis B infection is low, most infections occur among high-risk adult populations including injection drug users and multiple heterosexual partners. On the contrary, in high prevalence areas, infection occurs during either the perinatal period or early in childhood. The risk of maternal-infant contamination is high, from 20 to 90 per cent according to the viral load. Vaccination prevents risk of infection and is strongly advised to persons at high risk of infection. Universal vaccination of infants is highly recommended.     

Seroepidemiologic study of human cytomegalovirus in pregnant women in Valiasr Hospital of Kazeroon,Fars, Iran

Background. Cytomegalovirus (CMV) is a common opportunistic infection among HIV-infected individuals, a major source of serious complications among organ-transplant recipients, and a leading cause of hearing loss, vision loss, and mental retardation among congenitally infected children. Women infected for the first time during pregnancy are especially likely to transmit CMV to their fetuses.

Objective. In this study, it was aimed to determine the rate of CMV seroprevalence in pregnant women, the prevalence of maternal CMV infection and also the incidence of congenital CMV infection in their newborns in the Kazeroon, south of Iran.

Methods. Between January 2007 and July 2007, all (n = 1472) pregnant women who attended the obstetric ward of Valiasr hospital in Kazeroon for delivery, were enrolled in this study, and according to the presence or absence of anti CMV-IgM and CMV-IgG, were classified as seropositive, seronegative and having active maternal CMV infection. Differentiation of primary and recurrent CMV infection in women with both CMV-IgM (+) and CMV-IgG (+) antibody was determined by the avidity index (AI) of anti-CMV IgG.

Results. The rate of seropositivity was found as 97.69% and the rate of seronegativity as 2.31% in pregnant women. The prevalence of active maternal CMV infection was found as 4.35% and among these pregnant women, the incidence of primary and recurrent maternal CMV infection was 34.4% and 65.6% respectively.

Conclusion. Seroprevalence rate of CMV in pregnant women is high and most infections are recurrent. Thus, it does not seem to be cost-effective to screen all pregnant women for CMV infection, as in the other countries with high seropositivity rate.